Radioimmunotherapy as a novel treatment regimen: 125I-labeled monoclonal antibody 425 in the treatment of high-grade brain gliomas

International Journal of Radiation Oncology Biology Physics

Volumn 58, Issue 3, 2004, Pages 972-975

  Quang, Tony S ^a   Brady, Luther W ^a  

^a HAHNEMANN UNIVERSITY HOSPITAL   (United States)

Author keywords

Brain tumor; Epidermal growth factor receptor; Glioma; Monoclonal antibody

Indexed keywords

BRAIN; CELLS; MONOCLONAL ANTIBODIES; PATIENT TREATMENT; RADIOTHERAPY; SURGERY; TUMORS;

BRAIN GLIOMAS; RADIOIMMUNOTHERAPY;

IMMUNOLOGY;

EPIDERMAL GROWTH FACTOR RECEPTOR; IODINE 125; IODINE 125 MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY; RADIOACTIVE IODINE; UNCLASSIFIED DRUG;

ACUTE TOXICITY; ANAPLASTIC CARCINOMA; ASTROCYTOMA; BEAM THERAPY; BLOOD; BRAIN TUMOR; CANCER ADJUVANT THERAPY; CANCER GRADING; CANCER RADIOTHERAPY; CANCER SURGERY; CANCER SURVIVAL; CLINICAL OBSERVATION; CLINICAL TRIAL; CONFERENCE PAPER; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE CONTROL; DRUG HALF LIFE; FEMALE; FOLLOW UP; GLIOBLASTOMA; GLIOMA; HUMAN; MAJOR CLINICAL STUDY; MALE; NAUSEA; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; POSTOPERATIVE PERIOD; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; RADIATION DOSE; RADIOACTIVITY; RADIOIMMUNOTHERAPY; STATISTICAL ANALYSIS; TUMOR CELL; VOMITING;

EID: 1242293091     PISSN: 03603016     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijrobp.2003.09.096     Document Type: Conference Paper

References (34)

1. Jemal A., Thomas A., Murray T., et al. Cancer statistics, 2002. Cancer J Clin. 52:2002;23-47.
2. Dropcho E.J., Soong S.J. The prognostic impact of prior low-grade histology in patients with anaplastic gliomas A case-control study . Neurology. 47:1996;684-690.
3. Simpson J.R., Horton J., Scott C.B., et al. Influence of location and extent of surgical resection on survival of patients with glioblastoma multiforme Results of three consecutive RTOG clinical trials . Int J Radiat Oncol Biol Phys. 22:1993;525-527.
4. Fischbach A.J., Martz K.L., Nelson J.S., et al. Long term survival in treated anaplastic astrocytomas. Am J Clin Oncol (CCT). 14:1991;365-370.
5. Brady L.W., Miyamoto C., Woo D.V., et al. Malignant astrocytomas treated with iodine-125 labeled monoclonal antibody 425 against epidermal growth factor receptor A phase II trial . Int J Radiat Oncol Biol Phys. 22:1991;225-230.
6. Libermann T.A., Razon N., Bartal A.D., et al. Expression of epidermal growth factor receptors in human brain tumors. Cancer Res. 44:1984;753-760.
7. Libermann T.A., Nusbaum H.R., Razon N., et al. Amplification, enhanced expression and possible rearrangement of EGF receptor gene in primary human-brain tumors of glial origin. Nature. 313:1985;144-147.
8. Libermann T., Nusbaum H., Razon N., et al. Amplification and overexpression of EGF receptor gene in primary human glioblastomas. J Cell Sci Suppl. 3:1985;161-172.
9. Von Deimling A., Louis D.N., von Ammon K., et al. Association of epidermal growth factor receptor gene amplification with loss of chromosome 10 in human glioblastoma multiforme. J Neurosurg. 77:1992;295-301.
10. Takahashi H., Herlyn D., Atkinson B., et al. Radioimmunodetection of human glioma xenographs by monoclonal antibody to epidermal growth factor receptor. Cancer Res. 47:1987;3847-3850.
11. 125I-labeled monoclonal antibody 425 against cancer cells containing epidermal growth factor receptor. Am J Clin Oncol (CCT). 15:1992;288-294.
12. Hendler F.J., Ozanne B.W. Human squamous cell lung cancers expressed increased epidermal growth factor receptors. J Clin Invest. 74:1984;647-651.
13. Gullick W.J., Marsden J.J., Whittle N., et al. Expression of epidermal growth factor receptors on human cervical, ovarian, and vulva carcinomas. Cancer Res. 46:1986;285-292.
14. Yamamoto T., Kamta N., Kawano H., et al. High incidence of amplification of the epidermal growth factor gene in human squamous carcinoma cells lines. Cancer Res. 46:1986;414-416.
15. Imai Y., Leung C.K.H., Friesen H.G., et al. Epidermal growth factor receptors and effect of epidermal growth factor on growth of human breast cancer cell lines in long-term tissue culture. Cancer Res. 42:1982;4394-4398.
16. Fitzpatrick S.L., LaChance M.P., Schultz G.S. Characterization of epidermal growth factor receptor and action on human breast cancer cells in culture. Cancer Res. 44:1984;3442-3447.
17. Sainsbury J.R.C., Farndon J.R., Sherbet G.V., et al. Epidermal-growth- factor receptors and oestrogen receptors in human breast cancer. Lancet. 1:1985;364-366.
18. Neal DE, Marsh C, Benett MK, et al. Epidermal-growth-factor receptors in human bladder cancer: Comparison of invasive and superficial tumours. Lancet 985;1:366-368.
19. Koprowski H., Herlyn M., Balaban G., et al. Expression of the receptor for epidermal growth factor correlates with increased dosage of chromosome 7 in malignant melanomas. Somatic Cell Mol Genet. 11:1985;297-302.
20. Real F.X., Rettig W.J., Chesa P.G., et al. Expression of epidermal growth factor receptor in human cultured cells and tissues Relationship to cell lineage and stage of differentiation . Cancer Res. 46:1986;4726-4731.
21. Hofer K.G., Hughes W.L. Radiotoxicity of intranuclear tritium, iodine-125, and iodine-131. Radiat Res. 47:1971;94-109.
22. Martin R.F., Haseltine W.A. Range of radiochemical damage to DNA with decay of iodine-125. Science. 213:1981;896-898.
23. Sunada H., Hagun B.E., Mendelsohn J., et al. Monoclonal antibody against epidermal growth factor receptor is internalized without stimulating receptor phosphorylation. Proc Natl Acad Sci USA. 83:1986;3825-3829.
24. 125I-labeled monoclonal antibody 17-1a in human cancer cells. Cancer Res. 49:1989;2951-2958.
25. Kwok T.T., Sutherland R.M. Cell cycle dependence of epidermal growth factor induced radiosensitization. Int J Radiat Oncol Biol Phys. 22:1992;525-527.
26. Rodeck U., Herlyn M., Herlyn D., et al. Tumor growth modulation by a monoclonal antibody to the epidermal growth factor receptor Immunologically mediated and effector cell-dependent effects . Cancer Res. 47:1987;3692-3696.
27. Woo D.V., Li D., Mattis J.A., et al. Selective chromosomaldamage and cytotoxicity of (125)I-labeled monoclonal antibody 17-1A in human cancer cells. Cancer Res. 49:1989;2951-2958.
28. Qin D.X., Zheng R., Tang J., et al. Influence of radiation on the blood brain barrier and optimum time of chemotherapy. Int J Radiat Oncol Biol Phys. 19:1990;1507-1510.
29. Brady L.W., Woo D.V., Markoe A., et al. Treatment of malignant gliomas with 125-I labeled monoclonal antibody against epidermal growth factor receptor. Antibody Immunoconj Radiopharm. 3:1990;169-179.
30. Brady L.W., Miyamoto C., Woo D.V., et al. Malignant astrocytomas treated with iodine-125 labeled monoclonal antibody 425 against epidermal growth factor receptor A phase II trial . Int J Radiat Oncol Biol Phys. 22:1992;225-230.
31. Brady L, Quang T, Emrich J, et al. A new treatment for high grade gliomas of the brain. In: Kogelnik HD, Lukas P, Sedlmayer E, editors. Progress in radio-Oncology VII. Proceedings of the 7th International Meeting on Progress in Radio-Oncology, May 15-19, 2002. Salzburg, Austria: Monduzzi Editore, 2002.
32. Emrich J.G., Emrich J.G., Brady L.W., et al. Radioiodinated (I-125) monoclonal antibody 425 in the treatment of high grade glioma patients Ten-year synopsis of a novel treatment . Am J Clin Oncol. 25:2002;541-546.
33. Bender H., Morabito M., Emrich J., et al. Pharmokinetic behavior of (125)I-labeled anti-epidermal growth factor receptor MAb 425 in high-grade glioma patients. Antibody Immunoconj Radiopharm. 5:1992;130.
34. Bender H, Emrich JG, Morabito MD, et al. Pre-injection of unlabeled monoclonal antibody improves the uptake of labeled antibody in glioma patients in vivo. In: European Journal of Nuclear Medicine, vol 20, abstract 186, abstracts of the European Association of Nuclear Medicine Congress, Lausanne, Switzerland, October 10-14, 1993.